HASTINGS DAVID C
SEC insider (Form 3/4/5 filer). CIK 0001237401. Insider at SCYNEXIS INC (SCYX) and 2 other issuers. 5 reported Form 4/5 transactions since Sep 2024; latest on Jun 26, 2026. Located in NEW HAVEN, CT.
Companies HASTINGS DAVID C has filed insider reports for
- SCYNEXIS INC (SCYX)
- Trevi Therapeutics, Inc. (TRVI): Officer, Chief Financial Officer
- Arbutus Biopharma Corp (ABUS): Officer, Chief Financial Officer
HASTINGS DAVID C
CIK: 0001237401
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)1 (20.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)4 (80.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Jun 26, 2026SCYX
SCYNEXIS INC
AwardDirect2.9K shares- - Jan 8, 2026TRVI
Trevi Therapeutics, Inc.
AwardDirectStock Option (right to buy)
375K shares- - Jun 26, 2025SCYX
SCYNEXIS INC
AwardDirect23K shares- - Feb 14, 2025ABUS
Arbutus Biopharma Corp
AwardDirect90.1K shares- - Feb 4, 2025ABUS
Arbutus Biopharma Corp
SaleDirect22.2K shares at avg. $3.28$73K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 26, 2026 |  SCYX SCYNEXIS INC | Award | 2,875 | - | $0 | Direct |
| Jan 8, 2026 |  TRVI Trevi Therapeutics, Inc. | Award Stock Option (right to buy) | 375,000 | - | - | Direct |
| Jun 26, 2025 | SCYX SCYNEXIS INC | Award | 23,000 | - | - | Direct |
| Feb 14, 2025 |  ABUS Arbutus Biopharma Corp | Award | 90,100 | - | - | Direct |
| Feb 4, 2025 | ABUS Arbutus Biopharma Corp | Sale | 22,183 | $3.28 | $72,827 | Direct |
1-5 of 5 transactions